Intercure (INCR) stock price is $3.47, up 5.31% on the day, as of Nov 6, 2026. It has a market cap of $36.12Mn, and is classified in the Cannabis industry (Consumer Staples sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap36.12 Mn
P/E-3.35
FCF (Yr)844,881.36
ROA (Yr)-5.02
EV to EBIT11.97
Net Income (Yr)-10.69 Mn
Enterprise Value-93.95 Mn
Add ratio to table…
About
InterCure Ltd. is an Israeli public corporation engaged in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use. The company operates licensed cultivation sites in Israel and maintains a network of pharmacies and distribution partners to supply its products to patients. In addition, InterCure Ltd. holds a non‑material biomed investment segment that focuses on strategic investments in life sciences and…
InterCure Ltd. is an Israeli public corporation engaged in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use. The company operates licensed cultivation sites in Israel and maintains a network of pharmacies and distribution partners to supply its products to patients. In addition, InterCure Ltd. holds a non‑material biomed investment segment that focuses on strategic investments in life sciences and medical innovation opportunities.
InterCure Ltd. generates revenue primarily from the sale of dried cannabis inflorescences and cannabis oil extracts to licensed pharmacies and distribution partners in Israel. The company also earns modest returns from its biomed investments through equity holdings and potential future milestones. Its products are sold under the CANNDOC brand and through partner brands such as Cookies, Givol, Leon Pharm and Max Pharm.
The company operates through the following segments:
Cannabis Production and Distribution: This segment encompasses the breeding, cultivation, processing, manufacturing and sale of pharmaceutical‑grade cannabis and cannabis‑based products for medical use, including the operation of the Northern and Southern facilities and the owned pharmacy chain.
Biomed Investments: This segment consists of strategic equity investments in life sciences and medical innovation companies, which currently represent a non‑material portion of overall activities.
InterCure Ltd. holds a leading position in the Israeli medical‑use cannabis market as one of the first licensed producers and a pioneer with over 18 years of operational experience. The company’s products meet IMCA‑certified IMC‑GAP, IMC‑GMP and IMC‑GDP standards, giving it a competitive advantage over rivals such as Aurora Cannabis Inc., Canopy Growth Corporation, Seah Medical Group, Village Farms Crop and Bedrocan International B. V. Strategic alliances with global players like Tilray, Organigram and Charlotte’s Web further strengthen its international footprint and access to complementary supply chains.
InterCure Ltd. serves licensed pharmacies, medical cannabis distributors and retail pharmacy chains across Israel. Specific customers include the Super‑Pharm pharmacy chain, Novolog, SLE, N. D. N., Pharma Zone and the company’s own pharmacy brands Givol™, Leon Pharm, Max Pharm and Cookies. The company also supplies products to international partners in the European Union and Canada pending regulatory approvals.
Sectors:Consumer Staples·Financial ServicesSector rationaleThe company's primary revenue is generated from the production, manufacturing, and sale of pharmaceutical-grade cannabis and cannabis-based products, which falls under the 'Cannabis' industry within Consumer Staples. A secondary sector of Financial Services is included because the company operates a distinct 'Biomed Investments' segment focused on strategic equity investments in life sciences companies.Industries:CannabisCannabisPrimaryInterCure is engaged in the cultivation, processing, and sale of pharmaceutical-grade cannabis and cannabis-based products for medical use. Its primary revenue is generated from the sale of dried cannabis inflorescences and cannabis oil extracts under the CANNDOC brand.PharmaciesPharmaciesSecondaryThe company operates its own pharmacy chain and sells products through pharmacy brands such as Givol, Leon Pharm, and Max Pharm, acting as a retailer of medical cannabis.Alternative Asset ManagersAlternative Asset ManagersSecondaryThe company maintains a Biomed Investments segment that focuses on strategic equity investments in life sciences and medical innovation companies.Classified using BQ-MICSCIK: 0001857030